


2003 Annual Conference on Antimicrobial Resistance

SCIENCE - PREVENTION - CONTROL

June 23-25, 2003 - Hyatt Regency Bethesda - Bethesda, Maryland



Sponsored by:



®

**National
Foundation for
Infectious
Diseases**


In Collaboration with:

APIC
ASSOCIATION FOR PROFESSIONALS IN
INFECTION CONTROL AND EPIDEMIOLOGY, INC.
Association for Professionals
in Infection Control and
Epidemiology, Inc.


APUA
Alliance for the Prudent
Use of Antibiotics


CDC
Centers for Disease
Control and Prevention


Environmental
Protection Agency


Center for Drug
Evaluation and Research
Food and Drug Administration


IDSA
Infectious Diseases
Society of America


National Institute of Allergy
and Infectious Diseases


Society for Healthcare
Epidemiology of America


United States
Department of Agriculture

Final Call for Abstracts and Conference Announcement

Conference Overview

Who Should Attend?

- Healthcare professionals and researchers in academia, government and industry with responsibility for, or an interest in, antimicrobial resistance
- Microbiologists
- Pharmacologists
- Pharmacoepidemiologists
- Public health officials
- Infectious diseases physicians
- Hospital epidemiologists and infection control practitioners
- Veterinarians
- Others with an interest in antimicrobial resistance

Conference participants should have a knowledge of or interest in antimicrobial resistance.

Acknowledgments (as of February 3, 2003)

This conference is supported, in part, through unrestricted educational grants from:

- Abbott Laboratories
- AstraZeneca Pharmaceuticals
- Aventis Pharmaceuticals
- Cubist Pharmaceuticals, Inc.
- The Ellison Medical Foundation
- Genome Therapeutics Corporation
- GlaxoSmithKline, Inc.
- Ortho-McNeil Pharmaceutical
- Pfizer, Inc.
- Roche Laboratories, Inc.
- Schering-Plough Research Institute

Conference Objectives

At the conclusion of this conference, participants should be able to meet the following overall conference objectives and session specific objectives:

Overall Conference Objectives

- Discuss the science, prevention and control of antimicrobial resistance.
- Define issues and potential solutions to the problem of antimicrobial resistance.

Session-Specific Objectives

Keynote Address

- Examine how numerous health catastrophes are occurring simultaneously and creating a global health disaster

Surveillance of Antimicrobial Resistance and Antimicrobial Usage

- Understand methodological issues that can affect the results obtained from systems designed to monitor drug resistance in community-acquired organisms
- Determine the strategies used to overcome challenges of establishing an automated surveillance system that directly communicates with hospital laboratories internationally
- Highlight the FDA efforts to obtain surveillance information on antimicrobial susceptibility patterns and efforts to link this information to drug utilization patterns
- Describe resistance patterns for Salmonella, Campylobacter, *E. coli* and Enterococcal isolates originating from food animals
- Outline scientific issues related to conducting national surveillance of antimicrobial resistance among human enteric bacteria

Contemporary Issues in Non-HIV Viral Resistance

- Analyze the mechanisms of antiviral resistance and list the differences in the frequency, biological effects and transmissibility of Influenza A viruses
- Determine the clinical consequences of emergence of lamivudine resistance in chronic hepatitis B
- Describe the mechanisms of antiviral resistance to ganciclovir in cytomegalovirus and list treatment options for patients failing ganciclovir therapy

- List the clinical features of drug-resistant infections due to herpes simplex virus and varicella-zoster viruses and understand the management alternatives

The Danish Experience of Eliminating Antibiotic Growth Promotants Has Been Beneficial and Could Be Replicated in the U.S.: Point/Counterpoint

- Explain the consequences of eliminating antibiotic growth promotants in Denmark and assess the feasibility, risks, and benefits of a similar ban in the U.S.

Novel Antimicrobial Alternatives

- Justify and describe immunotherapeutic approaches to serious resistant bacterial infections including vaccination, hyperimmunoglobulin and monoclonal antibody approaches
- Explain the utility of phage therapy for the treatment of VRE infections in the ICU environment
- Provide an example of utilization of probiotics to prevent resistant infections

Issues in Antimicrobial Drug Discovery and Development

- Compare and contrast the incentives for antimicrobial drug discovery versus pharmaceuticals for non-infectious conditions
- List and discuss at least two economic and regulatory incentives for antimicrobial drug development
- Discuss the regulatory issues in clinical trials of antimicrobial drugs for resistant pathogens.

Rapid Diagnostics for Infectious Diseases

- Discuss how provider barriers to limiting antibiotic use might be overcome with rapid infectious diseases diagnostics
- List three promising rapid diagnostic tests on the near horizon (within three to five years)
- Enumerate and discuss two unintended consequences of rapid diagnostics

International Problems in Antimicrobial Resistance

- Illustrate patterns of antimicrobial drug sales in Nigeria and assess implications for the spread of antimicrobial resistance
- Explain the ethical issues in conducting clinical trials in developing countries
- Describe and analyze geographic differences in antimicrobial resistance, providing at least two examples

CME Accreditation Statement

The National Foundation for Infectious Diseases (NFID) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education (CME) for physicians. NFID takes responsibility for the content, quality, and scientific integrity of this CME activity.

CME Credit Statement

The National Foundation for Infectious Diseases (NFID) designates this CME activity for a maximum of 18 credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.



Committees

Conference Organizing Committee

David M. Bell, M.D.
Centers for Disease Control and
Prevention
Atlanta, GA

P. Joan Chesney, M.D.
University of Tennessee Health
Science Center
Memphis, TN

J. Thomas McClintock, Ph.D.
U.S. Environmental
Protection Agency
Washington, DC

Stuart H. Cohen, M.D.
University of California, Davis
Medical Center
Sacramento, CA

Dale N. Gerding, M.D.
Northwestern Memorial
Hospital
Chicago, IL

Gayle K. Gilmore, RN, MA
Association for Professionals
in Infection Control and
Epidemiology
Duluth, MN

Stuart B. Levy, M.D.
Tufts University School of
Medicine
Boston, MA

William J. Martone, M.D.
National Foundation for
Infectious Diseases
Bethesda, MD

Marissa Miller, D.V.M., M.P.H.
National Institutes of Health
Bethesda, MD

John H. Powers, M.D.
Food and Drug Administration
Rockville, MD

Jane F. Robens, D.V.M.
U.S. Department of Agriculture
Beltsville, MD

David Ross, M.D., Ph.D.
U.S. Food and Drug
Administration
Rockville, MD

Scientific Program Committee

David M. Bell, M.D.
*Member, Conference
Organizing Committee*

P. Joan Chesney, M.D.
*Member, Conference
Organizing Committee*

J. Thomas McClintock, Ph.D.
*Member, Conference
Organizing Committee*

Mitchell L. Cohen, M.D.
Centers for Disease Control and
Prevention
Atlanta, GA

Stuart H. Cohen, M.D.
*Member, Conference
Organizing Committee*

George M. Eliopoulos, M.D.
Beth Israel Deaconess
Medical Center
Boston, MA

Fred M. Gordin, M.D.
VA Medical Center
Washington, DC

Dale N. Gerding, M.D.
*Member, Conference
Organizing Committee*

Gayle K. Gilmore, RN, MA
*Member, Conference
Organizing Committee*

**Shannon H. Goldwater,
Pharm.D.**
Pharmacia Corporation
Alexandria, VA

Frederick G. Hayden, M.D.
University of Virginia Health
Sciences Center
Charlottesville, VA

Stuart B. Levy, M.D.
*Member, Conference
Organizing Committee*

William J. Martone, M.D.
*Member, Conference
Organizing Committee*

Marissa Miller, D.V.M., M.P.H.
*Member, Conference
Organizing Committee*

John H. Powers, M.D.
*Member, Conference
Organizing Committee*

John H. Rex, M.D.
University of Texas Health
Sciences Center
Houston, TX

Jane F. Robens, D.V.M.
*Member, Conference
Organizing Committee*

David Ross, M.D., Ph.D.
*Member, Conference
Organizing Committee*

Daniel F. Sahn, Ph.D.
Chief Scientific Officer
Focus Technologies, Inc.
Herndon, VA

Merle A. Sande, M.D.
University of Utah School of
Medicine
Salt Lake City, UT

Francis P. Tally, M.D.
Cubist Pharmaceuticals, Inc.
Lexington, MA

Richard J. Whitley, M.D.
Children's Hospital
Birmingham, AL

Executive Staff Members

Sharon Cooper-Kerr
Director, Events Planning
National Foundation for
Infectious Diseases
Bethesda, MD

Sheena L. Majette
*Director, Continuing Medical
Education*
National Foundation for
Infectious Diseases
Bethesda, MD

Len Novick
Executive Director
National Foundation for
Infectious Diseases
Bethesda, MD

Preliminary Program

Sunday, June 22, 2003

7:00 p.m. -
9:00 p.m.

Registration

Monday, June 23, 2003

7:00 a.m. -
8:00 a.m.

Registration

7:30 a.m.

Continental Breakfast

8:00 a.m.

Welcome and Introductions

Keynote Address

8:05 a.m.

**Betrayal of Trust: The Collapse
of Global Public Health**

Laurie Garrett, Author
New York City, NY

8:55 a.m.

Questions and Answers

Symposium 1. Surveillance of Antimicrobial Resistance and Antimicrobial Usage

9:00 a.m.

**The In's and Out's of Surveillance
for Resistance in Community-
Acquired Infections: The Drug-Resistant
Streptococcus pneumoniae Model**

Cynthia G. Whitney, M.D., M.P.H.
*Centers for Disease Control
Atlanta, GA*

9:25 a.m.

Questions and Answers

9:30 a.m.

**Electronic Surveillance: Tracking
Antimicrobial Resistance and Beyond**

Daniel F. Sahn, Ph.D.
*Focus Technologies
Herndon, VA*

9:55 a.m.

Questions and Answers

10:00 a.m.

Coffee Break

10:30 a.m.

**FDA Perspectives on Issues in the
Surveillance of Antimicrobial Use**

John H. Powers, M.D.
*U.S. Food and Drug Administration
Rockville, MD*

10:55 a.m.

Questions and Answers

11:00 a.m.

**Trends in Antimicrobial Resistance:
Animal National Antimicrobial
Resistance Monitoring System**

Paula J. Fedorka Cray, Ph.D.
*U.S. Department of Agriculture
Athens, GA*

11:25 a.m.

Questions and Answers

11:30 a.m.

**Seven Years of National Surveillance
of Antimicrobial Resistance Among
Human Enteric Bacteria: Lessons Learned
and Trends Observed.**

Frederick J. Angulo, Ph.D., M.S.,
M.P.V.M.
*Centers for Disease Control
and Prevention
Atlanta, GA*

11:55 a.m.

Questions and Answers

12:00 p.m.

Lunch

Submitted Presentations

1:00 p.m.

Submitted presentations

Symposium 2. Contemporary Issues in Non-HIV Viral Resistance

2:30 p.m.

Influenza

Frederick G. Hayden, M.D.
*University of Virginia
Charlottesville, VA*

2:55 p.m.

Questions and Answers

3:00 p.m.

Hepatitis B

Anna S.F. Lok, M.D.
*University of Michigan
Ann Arbor, MI*

3:25 p.m.

Questions and Answers

3:30 p.m.

Coffee Break

4:00 p.m.

Cytomegalovirus (CMV)

Paul D. Griffiths, M.B.B.S, M.D.
*Royal Free Hospital London
London, UK*

4:25 p.m.

Questions and Answers

4:30 p.m.

**Herpes Simplex and Varicella-Zoster
Viruses (HSV and VZV)**

John W. Gnann, M.D.
*University of Alabama-Birmingham
Birmingham, AL*

Preliminary Program (continued)

4:55 p.m. **Questions and Answers**

5:00 p.m. **Adjournment**

Tuesday, June 24, 2003

7:00 a.m. -
8:00 a.m.

Registration and Poster Set-up

7:30 a.m.

Continental Breakfast

Symposium 3.
**The Danish Experience of Eliminating
Antibiotic Growth Promotants Has
Been Beneficial and Could be Replicated
in the U.S.: Point/Counterpoint**

8:00 a.m.

Pro
Henrik C. Wegener, Ph.D., M.Sc.
*Danish Zoonosis Center
Copenhagen, Denmark*

8:20 a.m.

Con
Paul Sundberg, D.V.M., Ph.D.
*National Pork Board
Des Moines, IA*

8:40 a.m.

Rebuttal: Pro

8:50 a.m.

Rebuttal: Con

9:00 a.m.

Questions and Answers

9:30 a.m.

Coffee Break

Symposium 4.
Novel Antimicrobial Alternatives

10:00 a.m.

**Immunotherapeutics for Resistant
Infections**
Joseph M. Patti, Ph.D.
*Inhibitix, Inc.
Alpharetta, GA*

10:25 a.m.

Questions and Answers

10:30 a.m.

Phage Therapy Against VRE Infections
Alexander Sulakvelidze, Ph.D.
*Intralytix, Inc.
Baltimore, MD*

10:55 a.m.

Questions and Answers

11:00 a.m.

**Probiotics: A Novel Approach to Combat
Resistant Infections**
Dale N. Gerding, M.D.
*Northwestern Memorial Hospital
Chicago, IL*

11:25 a.m.

Questions and Answers

Submitted Presentations

11:30 a.m.

Submitted Presentations

12:30 p.m.

Lunch

Symposium 5.
**Issues in Antimicrobial Drug
Discovery and Development**

2:00 p.m.

**Economic Incentives for Antimicrobial
Drug Discovery**
Scott M. Rocklage, Ph.D.
*Cubist Pharmaceuticals, Inc.
Lexington, MA*

2:25 p.m.

Questions and Answers

2:30 p.m.

**How Should We Go About Developing
Less Marketable Antimicrobial Drugs?**
Francis P. Tally, M.D.
*Cubist Pharmaceuticals, Inc.
Lexington, MA*

2:55 p.m.

Questions and Answers

3:00 p.m.

**Regulatory Incentives for Antimicrobial
Drug Development**
Mark Goldberger, M.D., M.P.H.
*U.S. Food and Drug Administration
Rockville, MD*

3:25 p.m.

Questions and Answers

3:30 p.m.

**Regulatory Issues in Clinical Trials
of Antimicrobial Drugs for
Resistant Pathogens**
John H. Powers, M.D.
*U.S. Food and Drug Administration
Rockville, MD*

3:55 p.m.

Questions and Answers

4:00 p.m.

Coffee Break

**Symposium 6.
Rapid Diagnostics for
Infectious Diseases**

- 4:20 p.m. **The Role of Rapid Diagnostics in the Development of Narrow Spectrum Antimicrobics**
Daniel S. Shapiro, M.D.
*Boston University School of Medicine
Boston, MA*
- 4:40 p.m. **Current Status of Rapid Diagnostics in Infectious Diseases**
Michael Miller, M.D.
*Centers for Disease Control and Prevention
Atlanta, GA*
- 5:00 p.m. **Can Antimicrobial Use Be Improved By Rapid Diagnostic Testing?**
Stuart H. Cohen, M.D.
*University of California, Davis Medical Center
Sacramento, CA*
- 5:20 p.m. **Unintended Consequences of Rapid Diagnostics**
Daniel F. Sahm, Ph.D.
*Focus Technologies
Herndon, VA*
- 5:40 p.m. - 6:00p.m. **Panel Discussion**
- 6:30 p.m. **Poster Reception**

Wednesday, June 25, 2003

- 7:00a.m. -8:00 a.m. **Registration**
- 7:30 a.m. **Continental Breakfast**
- Submitted Presentations**
- 8:30 a.m. **Submitted Presentations**
- 10:00 a.m. **Coffee Break**

**Symposium 7.
International Problems in
Antimicrobial Resistance***

- 10:30 a.m. **Unregulated Sales of Antimicrobials**
Iruka N. Okeke, Ph.D.
*Haverford College
Haverford, PA*
- 10:55 a.m. **Questions and Answers**
- 11:00 a.m. **Scientific Issues in Clinical Trials in Developing Countries**
Thomas C. Quinn, M.D.
*Johns Hopkins University
Baltimore, MD*
- 11:25 a.m. **Questions and Answers**
- 11:30 a.m. **Ethics of Clinical Trials in Developing Countries**
James V. Lavery, Ph.D.
*Fogarty International Center, National Institutes of Health
Bethesda, MD*
- 11:55 a.m. **Questions and Answers**
- 12:00 p.m. **Epidemiology of Antimicrobial Resistance in Europe: Geographic Differences**
Herman Goossens, M.D., Ph.D.
*University Hospital Antwerp
Edegem-Antwerp*
- 12:25 p.m. **Questions and Answers**
- 12:30 p.m. **Adjournment/Participant Evaluation**

**Meeting – Interagency Task Force
on Antimicrobial Resistance**

- 1:30 p.m. **A Public Health Action Plan to Combat Antimicrobial Resistance (Part I: Domestic Issues): Meeting for Public Comment on the Antimicrobial Resistance Interagency Task Force Annual Report**
Interagency Task Force on Antimicrobial Resistance
Co-Chaired by Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institutes of Health (NIH)

* Support for Symposium 7 was provided through an unrestricted educational grant to the National Foundation for Infectious Diseases from The Ellison Medical Foundation.

General Information

Language

The official language for the conference is English.

Dates and Location

The 2003 Conference on Antimicrobial Resistance will be held June 23-25, 2003 at the following hotel:

Hyatt Regency Bethesda*
One Bethesda Metro Center
Wisconsin Avenue at Old
Georgetown Rd.
Bethesda, Maryland 20814
(301) 657-1234

* **This facility is fully accessible to the public in accordance with the Americans with Disabilities Act guidelines.**

Hotel Accommodations

A limited number of guest rooms have been reserved at the Hyatt Regency Bethesda for conference participants at the rate listed below:

\$150 single/\$175 double occupancy (plus applicable taxes, currently \$12) per night.

To make a reservation, call the hotel directly at 301-657-1234 or the Hyatt toll-free reservation department at 800-233-1234, and **tell the agent that you are attending the 2003 Conference on Antimicrobial Resistance** being held from June 23-25, 2003. Reservations should be made **no later than May 25, 2003** in order to secure the conference rate. After that date, rooms are on a space- and

rate-available basis only. *Please note that the room block is limited, and contacting the hotel before May 25 does not guarantee that space will be available. Make your reservations as early as possible to avoid any problems.*

Travel

By Plane:

- **Baltimore-Washington International Airport (BWI)** is located approximately 40 minutes from the Hyatt Regency Bethesda. Taxi service between BWI and Bethesda is approximately \$60 one-way. Super Shuttle transportation service operates 24 hours a day, 7 days a week (call 1-800-258-3826 for reservations). The cost is approximately \$26 one-way and \$8 per additional person.
- **Washington Ronald Reagan-National Airport (DCA)** is located approximately 30 minutes from the Hyatt Regency Bethesda. Taxi service between Reagan-National Airport and Bethesda is approximately \$30 one-way. Super Shuttle transportation service operates 24 hours a day, 7 days a week (call 1-800-258-3826 for reservations). The cost is approximately \$17 one-way and \$8 per additional person. There is also convenient access to the *Metrorail* subway system. From National Airport station, take the Yellow line train in the direction of *Gallery Place*. Change trains at *Gallery Place*.

Take the Red line train in the direction of *Shady Grove/Grosvenor*. Disembark at the *Bethesda* station. The hotel is directly above the station.

- **Dulles International Airport (IAD)** is located approximately 35 minutes from the Hyatt Regency Bethesda. Taxi service between Dulles and Bethesda is approximately \$35 one-way. Super Shuttle transportation service operates 24 hours a day, 7 days a week (call 1-800-258-3826 for reservations). The cost is approximately \$21 one-way and \$10 per additional person.

By Train:

The Hyatt Regency Bethesda is located 25 minutes from Washington Union Station. A taxi will cost approximately \$20. Union Station is also serviced by the *Metrorail* subway system. From *Union Station*, take the Red line train in the direction of *Shady Grove/Grosvenor*. Disembark at the *Bethesda* station. The hotel is directly above the station.

By Car:

- **From Baltimore/New York:** Take 95 South to 495 West (toward Silver Spring). Follow 495 to Exit 33 (Connecticut Avenue). Turn left onto Connecticut Avenue heading towards Chevy Chase. Proceed south on Connecticut Avenue for approximately 1 mile. Turn right onto Route 410 (East-West Highway). Proceed on East-West Highway for 1 mile until it intersects with Route 355 (Wisconsin Avenue). Turn left

onto Wisconsin Avenue. The Hyatt is immediately on the right.

- **From Virginia:** Take 95 North to 495 North (towards Tysons Corner). Follow 495 North to Exit 34 (Wisconsin Avenue/Bethesda). Proceed on Wisconsin Avenue for approximately 2.5 miles. The Hyatt is on the right immediately after Old Georgetown Road.
- **From Frederick/Hagerstown:** Take I-70/ I-270 South towards Washington. Follow 270 South, bear left at the split (495 East). Continue on 495 to 355 South Exit (exit will be on the left). Proceed on 355 (Wisconsin Avenue) for approximately 2.5 miles. The Hyatt is on the right immediately after Old Georgetown Road.

If you require more detailed directions, please contact the hotel directly at 301-657-1234.

Parking at the Hotel: Parking for overnight guests is approximately \$10 (self-park)/ \$12 (valet). Daily parking rate is approximately \$7 per day and is based upon availability. Additional hourly parking lots are located nearby. For more information call 301-657-1234.

Recommended Dress

Business attire is appropriate for the sessions and receptions.

Reminder: Meeting room temperatures and personal comfort levels vary widely. Because meeting rooms often seem cold, please bring a sweater or jacket.

International Attendees

If you require a letter of invitation in order to obtain a visa for entry into the United States, please let us know as soon as possible. Please indicate where the letter should be sent and how it should be sent (fax, post, etc.)

Financial Support

Please note that the conference does **not** have funds available to support registration, travel, or any other costs of registrants. Reductions in registration fees are **not** available except for the early registration fee.

Abstract Submission

2003 Annual Conference on Antimicrobial Resistance

The Scientific Program Committee invites submissions of abstracts of original research. Topic areas and abstract format are available on-line at the conference website. All abstracts must be submitted electronically. Abstracts should be submitted via the on-line submission program on the conference website (www.nfid.org/conferences/resistance03).

Deadline: Abstracts must be received by April 1, 2003

Notification: Notification of Abstract acceptance will be e-mailed on or around April 15, 2003.

Important Note: Those whose abstracts are accepted for presentation must complete a conference registration and pay the appropriate registration fee by May 16, 2003; otherwise the abstract will be withdrawn. The conference does not have funds available to support travel or other costs, so please make financial arrangements as soon as possible. Presenters who fail to appear at the conference at the specified time(s) without making arrangements for a co-author to make their presentation will forfeit their registration fee and any future abstract submissions will be automatically disqualified from consideration for 2 years.

More Information: Additional information regarding the abstract submission process may be acquired by contacting Sheena Majette through any of the means listed below:

Phone: 301-656-0003 x12 **Fax:** 301-907-0878 **E-Mail:** resistance@nfid.org